@FiercePharma: Sanofi's new 6-in-1 vaccine won backing from Europe's CHMP. Would compete with $GSK's Infanrix Hexa. News | Follow @FiercePharma
@EricPFierce: Elan CEO Martin gives shareholders a taste of honey. More | Follow @EricPFierce
@AlisonBFierce: The flu vaccine was effective in only 56% of those who received it, largely failing to protect against the elderly. More | Follow @AlisonBFierce
> Ranbaxy is resuming production of generic Lipitor, which it halted after the recall of some lots because they might have been tainted by ground glass. Story
> Kentucky has filed suit against GlaxoSmithKline ($GSK), accusing it of some of the same kinds of indiscretions with Avandia which figured into its $3 billion settlement last year with the feds. News
> Florida has joined the states looking at legislating limits on biosimilars. More
> Some insurers are raising questions about the $235,000 cost of Juxtapid, a treatment for people with extremely high cholesterol who currently have to have their blood filtered. Story
> Roche ($RHHBY) subsidiary Genentech expects to fill nearly 600 new positions this year, many at their South San Francisco headquarters. Item
@FierceMedDev: Abbott chops 200 jobs at Ireland plant. Story | Follow @FierceMedDev
@MarkHFierce: A cancer diagnostic test you could use yourself in the bathroom at home? It's coming... More | Follow @MarkHFierce
@DamianFierce: Despite a revenue jump, Volcano's profits tanked in Q4. News | Follow @DamianFierce
> J&J's DePuy recalls knee component over risk of limb loss. Story
> Stryker sued over metal-hip safety shortfalls. Item
> Abiomed gets out from under FDA's Impella warning letter. Report
Biotech News
@FierceBiotech: FDA approved T-DM1 for patients with HER2-positive breast cancer. Story | Follow @FierceBiotech
@JohnCFierce: Elan lines up biotech deals as it preps for $3B Tysabri windfall. Report | Follow @JohnCFierce
> India probes cause of 436 clinical trial deaths. Item
> J&J stakes out Boston/Cambridge HQ for new innovation center. Report
> Report: Booming Genentech plans 600 new hires in 2013. News
> Upstart Blaze banks $8.5M A round for new cancer surgery tech. Article
And finally... The $162.6 million reduction in the assessed valuation of a Genentech facility in Hillsboro, OR, has put a world of hurt on that town's municipal budget. Story